Insider lines up multimillion-dollar stock sale at Rhythm Pharmaceuticals (NASDAQ: RYTM)

Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for treating acquired hypothalamic obesity. The drug, approved by Japan's Ministry of Health, showed an 18.8% placebo-adjusted BMI reduction in trials. It's the first approved therapy for this condition in Japan, with 5,000-8,000 potential patients. RYTM also markets the drug in the U.S. and Europe for similar indications.

Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for acquired hypothalamic obesity after regulatory approval and NHI listing. This is the first approved therapy in Japan for this condition, marking the company's geographic expansion of setmelanotide. Investors will watch for uptake metrics and revenue contributions in future quarters.

Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for acquired hypothalamic obesity, the first approved treatment for this condition in the country. The drug was included in Japan's National Health Insurance list, following MHLW approval in August. Rhythm estimates 5,000-8,000 people in Japan may have this condition.

H.C. Wainwright raised its price target for Rhythm Pharmaceuticals (RYTM) to $130 from $105, maintaining a Buy rating. The stock trades at $90.78, with analysts' targets ranging from $105 to $160. Japan approved IMCIVREE for acquired hypothalamic obesity, supported by Phase 3 trial data. Rhythm reported Q2 2026 earnings, with revenue of $71.26 million, beating estimates. The company is not yet profitable but has 89% gross margins and 54% revenue growth over the last year.

Rhythm Pharmaceuticals (RYTM) announced Health Canada approved IMCIVREE for weight management in patients with acquired hypothalamic obesity, expanding its existing approvals. The drug is now indicated for patients aged four and older. The company expressed gratitude to the Canadian patient and healthcare community.

Health Canada approved Rhythm Pharmaceuticals' Imcivree for weight management in patients aged 4+ with acquired hypothalamic obesity. The approval is based on a Phase 3 trial showing an 18.8% placebo-adjusted BMI reduction. Imcivree is also approved in the U.S., Europe, and the UK for other obesity-related indications.